ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Why Four? NCI Official Challenged To Explain Rational For Proposed Number Of Groups

March 25, 2011

Mason Asks For Better Technology Transfer In Cancer Prevention

October 30, 1992

In Brief: Leonidas Platanias named director of Lurie Comprehensive Cancer Center

October 3, 2014

New Yorkers Agree Cancer Program Needs More Money

June 7, 1985

Targeting Men At High Risk Finds More Head & Neck Cancer

September 24, 2010

In Brief: Hew Approves Patent Request From U. Arizona; Califano Still Pondering Bioassay Program Fate

September 1, 1978